173 related articles for article (PubMed ID: 7742529)
21. Deletion of the p16 and p15 genes in human bladder tumors.
Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
[TBL] [Abstract][Full Text] [Related]
22. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia.
Cayuela JM; Madani A; Sanhes L; Stern MH; Sigaux F
Blood; 1996 Mar; 87(6):2180-6. PubMed ID: 8630377
[TBL] [Abstract][Full Text] [Related]
23. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
24. p16ink4a gene and hematological malignancies.
Quesnel B; Preudhomme C; Fenaux P
Leuk Lymphoma; 1996 Jun; 22(1-2):11-24. PubMed ID: 8724524
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
26. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Drexler HG
Leukemia; 1998 Jun; 12(6):845-59. PubMed ID: 9639410
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Hayette S; Thomas X; Bertrand Y; Tigaud I; Callanan M; Thiebaut A; Charrin C; Archimbaud E; Magaud JP; Rimokh R
Leukemia; 1997 Oct; 11(10):1696-9. PubMed ID: 9324291
[TBL] [Abstract][Full Text] [Related]
28. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas.
Gombart AF; Morosetti R; Miller CW; Said JW; Koeffler HP
Blood; 1995 Aug; 86(4):1534-9. PubMed ID: 7632961
[TBL] [Abstract][Full Text] [Related]
29. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
[TBL] [Abstract][Full Text] [Related]
31. p16 gene homozygous deletions in acute lymphoblastic leukemia.
Quesnel B; Preudhomme C; Philippe N; Vanrumbeke M; Dervite I; Lai JL; Bauters F; Wattel E; Fenaux P
Blood; 1995 Feb; 85(3):657-63. PubMed ID: 7833469
[TBL] [Abstract][Full Text] [Related]
32. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias.
Hebert J; Cayuela JM; Berkeley J; Sigaux F
Blood; 1994 Dec; 84(12):4038-44. PubMed ID: 7994022
[TBL] [Abstract][Full Text] [Related]
33. Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues.
Izumoto S; Arita N; Ohnishi T; Hiraga S; Taki T; Hayakawa T
Cancer Lett; 1995 Nov; 97(2):241-7. PubMed ID: 7497469
[TBL] [Abstract][Full Text] [Related]
34. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.
Kumanishi T; Zhang S; Ichikawa T; Endo S; Washiyama K
Jpn J Cancer Res; 1996 Jul; 87(7):691-5. PubMed ID: 8698617
[TBL] [Abstract][Full Text] [Related]
35. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
[TBL] [Abstract][Full Text] [Related]
36. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
[TBL] [Abstract][Full Text] [Related]
37. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Nakamaki T; Kawamata N; Schwaller J; Tobler A; Fey M; Pakkala S; Lee YY; Kim BK; Fukuchi K; Tsuruoka N
Br J Haematol; 1995 Sep; 91(1):139-49. PubMed ID: 7577621
[TBL] [Abstract][Full Text] [Related]
38. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
Elenitoba-Johnson KS; Gascoyne RD; Lim MS; Chhanabai M; Jaffe ES; Raffeld M
Blood; 1998 Jun; 91(12):4677-85. PubMed ID: 9616165
[TBL] [Abstract][Full Text] [Related]
39. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.
Hangaishi A; Ogawa S; Imamura N; Miyawaki S; Miura Y; Uike N; Shimazaki C; Emi N; Takeyama K; Hirosawa S; Kamada N; Kobayashi Y; Takemoto Y; Kitani T; Toyama K; Ohtake S; Yazaki Y; Ueda R; Hirai H
Blood; 1996 Jun; 87(12):4949-58. PubMed ID: 8652807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
